Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.45 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6897575 | 0.94 | FGFR1 (0.56) | FGFR1SLC22A6CYP3A4HPRT1ADORA2A | |
| SCHEMBL6903222 | 0.90 | SLC22A6 (0.55) | FGFR1SLC22A6CYP3A4HPRT1ADORA2A | |
| SCHEMBL6316076 | 0.89 | FGFR1 (0.61) | FGFR1SLC22A6CYP3A4HPRT1ADORA2A | |
| SCHEMBL6904277 | 0.89 | FGFR1 (0.61) | FGFR1SLC22A6CYP3A4HPRT1ADORA2A | |
| SCHEMBL6905174 | 0.89 | FGFR1 (0.61) | FGFR1SLC22A6CYP3A4HPRT1ADORA2A | |
| SCHEMBL6904118 | 0.88 | FGFR1 (0.60) | FGFR1SLC22A6CYP3A4HPRT1ADORA2A | |
| SCHEMBL6905447 | 0.88 | SLC22A6 (0.55) | FGFR1SLC22A6CYP3A4HPRT1ADORA2A | |
| SCHEMBL6905911 | 0.86 | FGFR1 (0.53) | FGFR1SLC22A6CYP3A4HPRT1ADORA2A | |
| SCHEMBL6905183 | 0.86 | FGFR1 (0.63) | FGFR1SLC22A6CYP3A4ADORA2AADORA2B | |
| SCHEMBL6690541 | 0.85 | FGFR1 (0.56) | FGFR1SLC22A6CYP3A4HPRT1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, POLR2H, NSUN3 | FGFR1 2799/4885SLC22A6 3360/4885CYP3A4 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.